Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: The GLOW2 study

European Respiratory Journal

Volumn 40, Issue 5, 2012, Pages 1106-1114

  Kerwin, Edward ^a   Hébert, Jacques ^c   Gallagher, Nicola ^d   Martin, Carmen ^d   Overend, Tim ^d   Alagappan, Vijay K T ^b   Lu, Yimeng ^b   Banerji, Donald ^b  

^a Clinical Research Institute of Southern Oregon   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Centre de Recherche Appliquée en Allergie de Québec   (Canada)

^d NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

Author keywords

Bronchodilator; Chronic obstructive pulmonary disease; Glycopyrronium bromide; Long acting muscarinic antagonist; NVA237; Tiotropium

Indexed keywords

GLYCOPYRRONIUM BROMIDE; PLACEBO; TIOTROPIUM BROMIDE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERANCE; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEART ATRIUM FIBRILLATION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SYNDROME DELINEATION; TREATMENT DURATION; URINARY TRACT INFECTION; URINE RETENTION; XEROSTOMIA;

BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; FEMALE; GLYCOPYRROLATE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES;

EID: 84868554172     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00040712     Document Type: Article

References (31)

1. Viegi G, Pistelli F, Sherrill DL, et al. Definition, epidemiology and natural history of COPD. Eur Respir J 2007; 30: 993-1013.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD 2011). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Available from www.goldcopd.org
3. Cooper N, Walker I, Knowles I. NVA237 has similar efficacy as tiotropium bromide against methacholine-induced bronchocon-striction and less systemic effect on cardiovascular variables in an anaesthetized rabbit model. Eur Respir J 2006; 28: Suppl. 50, 436s.
4. Trifilieff A, Cope N, Boivin JF, et al. The inhaled antimuscarinic receptor antagonist, NVA237 (glycopyrrolate), has a favorable side-effect profile in a Brown Norway rat lung function model when compared with tiotropium. Chest 2007; 132: 530a.
5. Fogarty C, Hattersley H, Di Scala L, et al. Bronchodilatory effects of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2011; 105, 3: 337-342.
6. Verkindre C, Fukuchi Y, Flémale A, et al. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2010; 104: 1482-1489.
7. Vogelmeier C, Verkindre C, Cheung D, et al. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulm Pharmacol Ther 2010; 23: 438-444.
8. D'Urzo A, Ferguson GT, van Noord JA, et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res 2011; 12: 156.
9. Global Initiative for Chronic Obstructive Lung Disease (GOLD 2008). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Available from www.goldcopd.org.
10. Witek TJ Jr, Mahler DA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J 2003; 21: 267-272.
11. Jones P, Lareau S, Mahler DA. Measuring the effects of COPD on the patient. Respir Med 2005; 99: Suppl. B, S11-S18.
12. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009; 25: 2043-2048.
13. O'Donnell DE, Webb KA. The major limitation to exercise performance in COPD is dynamic hyperinflation. J Appl Physiol 2008; 105: 753-755.
14. Beeh KM, Singh D, Di Scala L, et al. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J COPD 2012; 7: 503-513.
15. Spencer S, Calverley PM, Burge PS, et al. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23: 698-702.
16. Miravitlles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004; 59: 387-395.
17. Seneff MG, Wagner DP, Wagner RP, et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995; 274: 1852-1857.
18. Vestbo J. What is an exacerbation of COPD? Eur Respir Rev 2004; 13: 6-13.
19. Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002; 96: 700-708.
20. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
21. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacother-apy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-338.
22. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.
23. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
24. Tonnel AB, Perez T, Grosbois JM, et al. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis 2008; 3: 301-310.
25. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005; 143: 317-326.
26. Chan CK, Maltais F,Sigouin C, et al. A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Can Respir J 2007; 14: 465-472.
27. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.
28. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217-224.
29. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399-404.
30. Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171-1178.
31. Donohue JF, Jones PW. Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2011; 6: 35-45.